10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
65.05
+5.77 (9.73%)
Nov 9, 2026, 4:00 PM EST - Market closed
10x Genomics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 618.58 | 642.82 | 610.79 | 618.73 | 516.41 | 490.49 | |
Revenue Growth | -3.62% | 5.24% | -1.28% | 19.81% | 5.28% | 64.13% |
Cost of Revenue | 173.43 | 198.44 | 196.3 | 209.41 | 120.09 | 74.09 |
Gross Profit | 445.15 | 444.38 | 414.48 | 409.31 | 396.32 | 416.4 |
Selling, General & Admin | 292.41 | 310.13 | 343.24 | 343.33 | 295.8 | 257.56 |
Research & Development | 218.44 | 234.53 | 264.7 | 265.73 | 264.27 | 211.75 |
Operating Expenses | 510.85 | 544.67 | 607.94 | 609.06 | 560.07 | 469.31 |
Operating Income | -65.7 | -100.29 | -193.46 | -199.75 | -163.74 | -52.91 |
Interest Expense | - | - | -0 | -0.03 | -0.48 | -0.87 |
Interest & Investment Income | 21.72 | 20.05 | 18.93 | 16.89 | 6.65 | 0.21 |
Currency Exchange Gain (Loss) | -1.3 | 2.5 | -2.1 | 1.2 | 0.2 | -0.9 |
Other Non Operating Income (Expenses) | -3.08 | -1.47 | 0.03 | -1.49 | -0.4 | 0.1 |
EBT Excluding Unusual Items | -48.36 | -79.21 | -176.6 | -183.18 | -157.77 | -54.38 |
Merger & Restructuring Charges | -10.6 | -10.6 | - | - | -4.2 | - |
Asset Writedown | 0.7 | - | -1.1 | -4.6 | - | - |
Legal Settlements | 3.4 | 49.9 | - | - | - | 0.66 |
Other Unusual Items | -10.3 | - | - | - | - | - |
Pretax Income | -65.16 | -39.91 | -177.7 | -248.76 | -161.97 | -53.72 |
Income Tax Expense | 1.92 | 3.64 | 4.93 | 6.34 | 4.03 | 4.51 |
Net Income | -67.08 | -43.54 | -182.63 | -255.1 | -166 | -58.22 |
Net Income to Common | -67.08 | -43.54 | -182.63 | -255.1 | -166 | -58.22 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 129 | 125 | 120 | 117 | 114 | 110 |
Shares Outstanding (Diluted) | 129 | 125 | 120 | 117 | 114 | 110 |
Shares Change | 4.52% | 3.57% | 2.80% | 2.90% | 3.18% | 9.09% |
EPS (Basic) | -0.52 | -0.35 | -1.52 | -2.18 | -1.46 | -0.53 |
EPS (Diluted) | -0.52 | -0.35 | -1.52 | -2.18 | -1.46 | -0.53 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 93.77 | 130.12 | -5.73 | -63.8 | -165.27 | -122.65 |
Free Cash Flow Per Share | 0.73 | 1.04 | -0.05 | -0.55 | -1.45 | -1.11 |
Gross Margin | 71.96% | 69.13% | 67.86% | 66.15% | 76.75% | 84.89% |
Operating Margin | -10.62% | -15.60% | -31.67% | -32.28% | -31.71% | -10.79% |
Profit Margin | -10.84% | -6.77% | -29.90% | -41.23% | -32.15% | -11.87% |
Free Cash Flow Margin | 15.16% | 20.24% | -0.94% | -10.31% | -32.00% | -25.01% |
EBITDA | -26.51 | -64.09 | -157.58 | -164.24 | -138.38 | -31.8 |
EBITDA Margin | -4.29% | -9.97% | -25.80% | -26.54% | -26.80% | -6.48% |
D&A For EBITDA | 39.19 | 36.2 | 35.88 | 35.51 | 25.37 | 21.12 |
EBIT | -65.7 | -100.29 | -193.46 | -199.75 | -163.74 | -52.91 |
EBIT Margin | -10.62% | -15.60% | -31.67% | -32.28% | -31.71% | -10.79% |
Revenue as Reported | 618.58 | 642.82 | 610.79 | 618.73 | - | - |
Advertising Expenses | - | 2.5 | 3.9 | 3.3 | 3.7 | 4.7 |